Gilead Sciences

1. Regulatory Risk- The success of Gilead Sciences depends largely upon the approval of its products and programs by various governmental regulatory agencies. If the necessary approvals are not obtained in a timely fashion, or if approval is delayed or denied, then Gilead Sciences’ revenue and profitability may suffer.

2. Clinical Risk- There is a risk related to the success of clinical trials conducted by Gilead Sciences. If the results are negative, the efficacy of the product or program may be questioned and could lead to delays in obtaining regulatory approval or refusal of the product or program by the FDA or other regulatory agencies.

3. Competitor Risk- Gilead Sciences faces a significant risk from the presence of competitors in the market, as its products may become redundant or obsolete. The emergence of new products or technologies by competitors could put Gilead Sciences at a competitive disadvantage.

4. Intellectual Property Risk- Gilead Sciences may face significant risk to its intellectual property. If competitors are able to invalidate or infringe upon Gilead Sciences’ patents, then its ability to protect its products and program designs may be limited or weakened.